Genflow Biosciences PLC Announces Corporate Update

Genflow Biosciences Provides Half Year Corporate Update on SIRT6 Programs, IP Progress and Strategic Partnerships

LONDON, UK / ACCESS Newswire / June 17, 2025 / Genflow Biosciences Plc (LSE:GENF)(OTCQB:GENFF) ("Genflow" or "the Company"), the only publicly listed longevity company in Europe, is pleased to provide an update on the continued advancement of its core programs focused on the SIRT6-centenarian gene and its potential to slow aging and delay the onset of age-related diseases.

Since the start of the year, the Company has made meaningful progress across its research and development initiatives. These advancements have been supported by a strengthened leadership network of world-class academic collaborators and laboratories. Combined with the continued support of international institutional investors and previously awarded government grants, this ecosystem has played a vital role in accelerating Genflow's scientific and clinical development.

As part of its strategic execution, Genflow has signed a Master Service Agreement (MSA) with CER Groupe, a trusted long-term partner and leading Belgian research center specializing in integrated bioproduction and pre-clinical services. CER operates in a fully regulated ISO and GxP-compliant environment and will provide a robust R&D framework to support the advancement of Genflow's pre-IND gene therapy programs.

In parallel, the Company continues to expand its global intellectual property portfolio. In February, Genflow's exclusively out-licensed European Patent Office (EPO) application titled "Variants of SIRT6 for Use in Preventing and/or Treating Age-Related Diseases" advanced through the Supplementary European Search Report without objections, allowing it to proceed to the national phase-a key step toward securing protections across major European markets.

Similarly, the Japanese Patent Office has progressed the same SIRT6-related application (Application No. JP 2024515284) to the national examination phase, marking another important milestone in establishing global IP coverage for Genflow's innovative gene therapy technology.

Originally filed on 13 May 2022, the patent is jointly owned by the University of Rochester, The Trustees of Columbia University in the City of New York, and Albert Einstein College of Medicine. Genflow holds the exclusive worldwide license to this intellectual property.

To support the intellectual property costs associated with entering into the national phase in the U.S., Canada, Europe, Japan, Australia, China, Genflow has applied for a PATEX-2 grant in connection with its patent application PCT/EP2023/084840, titled "SIRT6 Variants for NASH," filed on December 8, 2023. This patent is fully owned by Genflow Biosciences.